UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

PloS one, 2015-03, Vol.10 (3), p.e0119509-e0119509

2015

Volltextzugriff (PDF)

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

PloS one, 2012-12, Vol.7 (12), p.e51618

2012

Volltextzugriff (PDF)

Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas

PloS one, 2012-08, Vol.7 (8), p.e42610-e42610

2012

Volltextzugriff (PDF)

Latent Membrane Protein 1 of EBV Activates Phosphatidylinositol 3-Kinase to Induce Production of IL-10

The Journal of immunology (1950), 2007-12, Vol.179 (12), p.8225-8234

2007

Volltextzugriff (PDF)

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Journal of immunotherapy (1997), 2022-04, Vol.45 (3), p.167-179

2022

Volltextzugriff (PDF)

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults

Journal of translational medicine, 2018-06, Vol.16 (1), p.153-153, Article 153

2018

Volltextzugriff (PDF)

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques

Vaccine, 2015-08, Vol.33 (36), p.4472-4478

2015

Volltextzugriff (PDF)

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay

Clinical and vaccine immunology, 2017-12, Vol.24 (12)

2017

Volltextzugriff (PDF)

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Clinical and vaccine immunology, 2017-09, Vol.24 (9)

2017

Volltextzugriff (PDF)

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults

Human vaccines & immunotherapeutics, 2019-10, Vol.15 (10), p.2466-2474

2019

Volltextzugriff (PDF)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

Clinical and translational science, 2021-01, Vol.14 (1), p.277-287

2021

Volltextzugriff (PDF)

Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers

Journal of virology, 2016-11, Vol.90 (22), p.10133-10144

2016

Volltextzugriff (PDF)

Tumor-derived Variants of Epstein-Barr Virus Latent Membrane Protein 1 Induce Sustained Erk Activation and c-Fos

The Journal of biological chemistry, 2008-12, Vol.283 (52), p.36573-36585

2008

Volltextzugriff (PDF)

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer

Cancer treatment and research communications, 2021, Vol.28, p.100405-100405, Article 100405

2021

Volltextzugriff (PDF)

EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis

Journal of Immunology, 2006-09, Vol.177 (5), p.3283-3293

2006

Volltextzugriff (PDF)

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

Immunity & ageing, 2012-10, Vol.9 (1), p.21-21, Article 21

2012

Volltextzugriff (PDF)

Abstract 1308: Development and validation of a flow cytometric assay for measuring glycoprotein A repetitions predominant protein GARP target engagement by ABBV-151

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1308-1308

2021

Volltextzugriff (PDF)

Abstract 153: Development of a workflow to handle the quality control and analysis of Olink protein biomarker data in early phase oncology clinical trials

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.153-153

2021

Volltextzugriff (PDF)

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Vaccine, 2016-05, Vol.34 (25), p.2847-2854

2016

Volltextzugriff (PDF)

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7067-TPS7067

2022

Volltextzugriff (PDF)

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

Blood, 2001-03, Vol.97 (5), p.1370-1377

2001

Volltextzugriff (PDF)

TCR Vaccines against a Murine T Cell Lymphoma: A Primary Role for Antibodies of the IgG2c Class in Tumor Protection

The Journal of immunology (1950), 2004-01, Vol.172 (2), p.929-936

2004

Volltextzugriff (PDF)

Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4464-4464

2020

Volltextzugriff (PDF)

Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT207-CT207

2021

Volltextzugriff (PDF)

MO2-12-4Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

Annals of oncology, 2019-10, Vol.30 (Supplement_6)

2019

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(60)
Dissertationen
(1)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas

Latent Membrane Protein 1 of EBV Activates Phosphatidylinositol 3-Kinase to Induce Production of IL-10

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers

Tumor-derived Variants of Epstein-Barr Virus Latent Membrane Protein 1 Induce Sustained Erk Activation and c-Fos

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer

EBV Can Protect Latently Infected B Cell Lymphomas from Death Receptor-Induced Apoptosis

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

Abstract 1308: Development and validation of a flow cytometric assay for measuring glycoprotein A repetitions predominant protein GARP target engagement by ABBV-151

Abstract 153: Development of a workflow to handle the quality control and analysis of Olink protein biomarker data in early phase oncology clinical trials

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

TCR Vaccines against a Murine T Cell Lymphoma: A Primary Role for Antibodies of the IgG2c Class in Tumor Protection

Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial

Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors

MO2-12-4Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

Suchergebnisse filtern